A Centennial Letdown for FDA's Biologics Group

See allHide authors and affiliations

Science  29 Nov 2002:
Vol. 298, Issue 5599, pp. 1704-1705
DOI: 10.1126/science.298.5599.1704

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


New leaders at the Food and Drug Administration are pushing a big shakeup of the division that oversees biologics in a way that seems to de-emphasize research, although they cite other reasons for making changes. However, many researchers at the Center for Biologics Evaluation and Research and outside scientists have begun arguing that the real purpose of the move is to strip away CBER's special status as a regulator that also supports substantial intramural research.